Dr. Dominique Demolle, CEO of Tools4Patient, recently presented data at the 16th Annual Scientific Meeting of the International Society for CNS Clinical Trials and Methodology in Washington, DC. The presentation, entitled ““Modeling of Peripheral Neuropathic Pain and Osteoarthritis Placebo Response: Working Towards a Unique Model of the Placebo Response in Chronic Pain?” was authored by Tools4Patient scientist Dr. Samuel
Topic: Placebell©™
In analgesia randomized clinical trials (RCTs), the magnitude and the variability of the placebo response negatively impacts the ability to demonstrate superiority of active compounds compared to placebo. The first objective of this analysis was to investigate parameters influencing the placebo response in PNP as a way to control for this major confounding factor.
Learn more about the development of the MPsQ and the its use as part of the Placebell©™ technology.
There is substantial scientific literature describing the placebo response in pain, including characterizing the magnitude and duration of placebo response in randomized clinical trials.
While drug developers have been struggling with the placebo response for decades, Placebell©™ is the first commercially available technology that enables scientists to control for the placebo response in clinical studies. Tools4Patient (T4P) launched Placebell©™ in late 2017,
In May 2018, Tools4Patient (T4P) presented a webinar entitled “Characterization of Individual Patient Placebo Response: Impact on the Clinical Study Power”.